SCHEDULE: BCLS Fund III Discloses 9.99% Stake in Cidara

BCLS Fund III Investments, LP has disclosed a 9.99% beneficial ownership stake in Cidara Therapeutics, Inc., comprising common and convertible preferred stock.

Summary

• BCLS Fund III Investments, LP reported a 9.99% beneficial ownership stake in Cidara Therapeutics, Inc. as of June 30, 2025.
• The Reporting Person beneficially owned 2,500,680 shares of Cidara Therapeutics, Inc. common stock.
• This ownership includes 703,080 shares of common stock and 89,956 shares of Series A Convertible Voting Preferred Stock.
• The preferred stock is convertible into an aggregate of 6,296,920 shares of common stock, but is subject to a beneficial ownership blocker.
• The blocker prohibits conversion if it would result in ownership exceeding 9.99% of the outstanding common stock.
• The percentage is calculated based on 23,234,839 common shares outstanding as of June 30, 2025, and 1,797,600 shares convertible from preferred stock, reflecting the maximum allowed under the blocker.
• The filing states the securities were not acquired for the purpose of changing or influencing control of the issuer, except for activities related to nominations under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or prospects.

Positives

• The filing is a factual disclosure of ownership and does not contain explicit positive statements regarding company performance or outlook.
• A significant stake by BCLS Fund III Investments, LP, an entity associated with Bain Capital Life Sciences, may be interpreted by the market as a vote of confidence in Cidara Therapeutics, Inc.

Negatives

• The filing is a factual disclosure of ownership and does not contain explicit negative statements regarding company performance or outlook.

Risks

• The Series A Convertible Voting Preferred Stock is subject to a beneficial ownership blocker, limiting conversion if it would result in the Reporting Person owning in excess of 9.99% of the outstanding common stock.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not provide any forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

This filing indicates a significant investment by a life sciences-focused fund, BCLS Fund III Investments, LP, in Cidara Therapeutics, Inc., a biotechnology company. Such investments are common in the life sciences sector, where specialized funds often take strategic stakes in companies developing novel therapies.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure of beneficial ownership, which is a regulatory requirement for investors acquiring more than 5% of a company's stock.
• The 9.99% stake held by BCLS Fund III Investments, LP is a substantial position, typical for institutional investors seeking influence or a significant return in a specific company within the biotechnology sector.
• There are no specific comparable companies or projects mentioned in this filing to assess results against.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by a prominent life sciences investor could be viewed positively, potentially signaling confidence in the company's future.
• Employees, Customers, Suppliers, Creditors: The filing, being a beneficial ownership report, does not directly impact these stakeholders in the short term, as it does not detail operational changes or financial performance.

Next Steps

• The filing does not specify any future actions, events, or milestones for the issuer or the reporting person beyond the ongoing regulatory compliance.

Key Dates

Keywords

Cidara Therapeutics, BCLS Fund III Investments, Bain Capital Life Sciences, SEC filing, Schedule 13G, beneficial ownership, common stock, preferred stock, biotechnology, pharmaceuticals